In This Article:
-
Revenue: $0.7 million for the fourth quarter.
-
Research and Development Expenses: $18.4 million for the fourth quarter, up from $12.3 million in the prior year period.
-
Selling, General, and Administrative Expenses: $8.8 million for the fourth quarter, down from $9.3 million in the prior year period.
-
Cash, Cash Equivalents, and Short-term Investments: $112.4 million as of December 31, 2024.
-
Full-Year Cash Usage: Approximately $72 million, below the projected $75 million.
-
Additional Funding: $40 million raised through a strategic collaboration with AMD and an at-the-market facility.
-
Financial Outlook: Existing cash expected to fund operations into the first half of 2027.
Release Date: March 18, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Absci Corp (NASDAQ:ABSI) successfully executed across all aspects of its business in 2024, including advancing proprietary internal programs and adding four new partners.
-
The company unveiled its potentially category-defining ABS-201 program, targeting the prolactin receptor for androgenic alopecia, with promising pre-clinical data.
-
Absci Corp's collaboration with AMD provides optimized compute solutions, enhancing performance and reducing costs for complex biological modeling.
-
The company demonstrated significant advancements in its AI-integrated drug creation platform, showcasing breakthroughs in de novo antibody design.
-
Absci Corp ended the year with a strong financial position, having raised an additional $40 million, extending its cash runway into the first half of 2027.
Negative Points
-
Revenue for the fourth quarter was only $0.7 million, indicating limited financial growth from partnered programs.
-
Research and development expenses increased significantly to $18.4 million, driven by internal program advancements and stock compensation expenses.
-
The company plans to stop providing exact numbers of expected new partners, which may reduce transparency for investors.
-
Absci Corp's cash, cash equivalents, and short-term investments decreased from $127.1 million to $112.4 million by the end of the year.
-
The company faces competition in the androgenic alopecia market, with no real innovation in nearly 30 years, posing challenges for ABS-201's market entry.
Q & A Highlights
Q: Does Absci plan to conduct additional pre-clinical studies with ABS-101 and ABS-201, and will investors see the results? A: Christian Stegmann, SVP of Drug Creation, stated that for ABS-101, they are wrapping up IND-enabling work and plan to disclose full toxicology data at a scientific conference. For ABS-201, they are in the IND-enabling phase and will disclose data during this process, also preferably at a scientific conference.